Access to Medications for Opioid Use Disorder for Persons With Human Immunodeficiency Virus in the United States: Gaps in Coverage by State AIDS Drug Assistance Programs

Kathleen A McManus; Thibaut Davy-Mendez; Amy Killelea; Asher J Schranz

doi:10.1093/ofid/ofac057

Access to Medications for Opioid Use Disorder for Persons With Human Immunodeficiency Virus in the United States: Gaps in Coverage by State AIDS Drug Assistance Programs

Open Forum Infect Dis. 2022 Mar 7;9(4):ofac057. doi: 10.1093/ofid/ofac057. eCollection 2022 Apr.

Authors

Kathleen A McManus¹, Thibaut Davy-Mendez², Amy Killelea³, Asher J Schranz²

Affiliations

¹ Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.
² Division of Infectious Diseases, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
³ Killelea Consulting, Arlington, Virginia, USA.

Abstract

Life-saving medications for opioid use disorder are inaccessible for people with human immunodeficiency virus relying on the AIDS Drug Assistance Programs (ADAP) in 40% of jurisdictions. Funding/policies should address this through increasing access through ADAP and the Ryan White HIV/AIDS Program (RWHAP), partnerships between RWHAP and substance use programs, and other state/federal initiatives.

Keywords: AIDS Drug Assistance Program; access to medications; health policy; opioid use disorder.

Abstract

Grants and funding